Global Chemotherapy Induced Peripheral Neuropathy Treatment Market to Reach $2.5 Billion by 2029, Growing at 9% CAGR

What combination of drivers is leading to accelerated growth in the chemotherapy induced peripheral neuropathy treatment market?
The escalating incidences of cancer globally are predicted to drive the growth of the market for treatment of chemotherapy-induced peripheral neuropathy. Cancer is distinguished by the unchecked proliferation and distribution of irregular cells within the body. Chemotherapy-induced peripheral neuropathy is a potential complication of specific chemotherapy drugs utilized in cancer therapy. As the rate of global cancer cases rise, so does the growth of the market for treating chemotherapy-induced peripheral neuropathy. For example, a report released by the American Cancer Society - a nationwide voluntary health organization in the US with the goal of eradicating cancer - in January 2023, illustrated an increase in diagnosed liver cancer cases in females in the US. The number increased from 12,660 in 2022 to 13,230 in 2023. As such, the growing occurrence of cancer is fueling the expansion of the market for chemotherapy-induced peripheral neuropathy treatment.

Get Your Chemotherapy Induced Peripheral Neuropathy Treatment Market Report Here:
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

What is the projected compound annual growth rate (CAGR) of the chemotherapy induced peripheral neuropathy treatment market from 2025 to 2034, and what factors influence it?
The market size of treatments for chemotherapy-induced peripheral neuropathy has seen substantial growth in the recent past. It is anticipated to increase from $1.66 billion in 2024 to $1.78 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.1%. Factors contributing to previous growth include advances in chemotherapy, the broadening of cancer treatments, limited available treatment alternatives, a rise in cancer cases, and developments in neurological research.

The market size for treatment of chemotherapy induced peripheral neuropathy is predicted to experience considerable expansion over the upcoming years, growing to a valuation of $2.5 billion in 2029 with a compound annual growth rate (CAGR) of 8.9%. The expected growth in this timeframe can be credited to advancements in targeted therapies, neuroprotective agents, comprehensive care pathways, patient-focused care models, and regulatory backing. Key trends anticipated in the forecast period encompass new drug formulations, non-medical interventions, therapies based on neuroplasticity, long-term survivor support, and cognitive behavioral treatments.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11967&type=smp

How are the latest trends influencing the growth of the chemotherapy induced peripheral neuropathy treatment market?
Product Innovation is gaining traction as a major trend in the chemotherapy-induced peripheral neuropathy treatment market. Key players within this market are focusing their efforts on introducing new innovations to enhance their monitoring capabilities and affirm their market stand. An example of such innovation emerged in March 2023, when AlgoTx - a company that excels in advanced pain management, announced FDA approval of its Investigational New Drug Application (IND) for ATX01 - a first-in-class candidate of Phase 2. This breakthrough treatment targets individuals dealing with erythromelalgia. Simultaneously, the first patients for ATX01 in the Pain of Chemotherapy (ACT) study concerning chemotherapy-induced peripheral neuropathy (CIPN) have been designated and randomized. These programs have successfully secured a fast-track designation from the FDA.

What are the major segments of the chemotherapy induced peripheral neuropathy treatment market and their role in driving growth?
The chemotherapy induced peripheral neuropathy treatment market covered in this report is segmented -

1) By Drug Class: Nerve Protective Therapy, Anti-Inflammatory Therapy, Neurotransmitter Based Therapy, Antioxidant, Other Drug Classes
2) By Treatment: Medication, Therapy, Other Treatments
3) By Drug Type: Branded, Generic
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospitals, Research Institutes, Specialty Clinics

Subsegments:
1) By Nerve Protective Therapy: Vitamin B Complex, Alpha-Lipoic Acid, Acetyl-L-Carnitine
2) By Anti-Inflammatory Therapy: Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
3) By Neurotransmitter Based Therapy: Gabapentin, Pregabalin, Duloxetine
4) By Antioxidant: N-acetylcysteine, Glutathione, Coenzyme Q10
5) By Other Drug Classes: Topical Treatments, Opioids, Herbal Remedies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11967

Which regions are key players in the growth of the chemotherapy induced peripheral neuropathy treatment market?
North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market in 2024. Asia-Pacific and Europe are expected to be the fastest-growing regions in the forecast period. The regions covered in the chemotherapy induced peripheral neuropathy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the chemotherapy induced peripheral neuropathy treatment market?
Major companies operating in the chemotherapy induced peripheral neuropathy treatment market include Hoffmann-La Roche Ltd., Midatech Pharma PLC, Novartis AG, Lee's Pharmaceutical Holdings Limited, RELIEF THERAPEUTICS Holding SA, Eurofins Advinus, WEX Pharmaceuticals Inc., Asahi Kasei Corporation, MediciNova Inc., Solasia Pharma K.K., ESTEVE, ChromaDex Inc., Apollo Endosurgery Inc., REGENACY PHARMACEUTICALS INC., Novaremed AG, MAKScientific LLC, Sova Pharmaceuticals Inc., Kineta Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., WinSanTor Inc., Alexion Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Acorda Therapeutics Inc., Galena Biopharma Inc., Incyte Corporation

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=11967&type=smp

What Is Covered In The Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report?

• Market Size Forecast: Examine the chemotherapy induced peripheral neuropathy treatment market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the chemotherapy induced peripheral neuropathy treatment market for a structured understanding.
• Key Players Overview: Analyze major players in the chemotherapy induced peripheral neuropathy treatment market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the chemotherapy induced peripheral neuropathy treatment market.
• Segment Contributions: Evaluate how different segments drive overall growth in the chemotherapy induced peripheral neuropathy treatment market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the chemotherapy induced peripheral neuropathy treatment market.
• Industry Challenges: Identify potential risks and obstacles affecting the chemotherapy induced peripheral neuropathy treatment market.
• Competitive Landscape: Review strategic developments in the chemotherapy induced peripheral neuropathy treatment market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.